Accelerated Breakthrough: Allist’s Q3 financial report. Performance overview:


Allist milestones

Furmonertinib achieves positive results from the study on the first-line treatment of advanced NSCLC.

Compared with the control group receiving the first-generation EGFR-TKI Gefitinib (Iressa®), the Furmonertinib treatment group showed statistically and clinically significant benefits of progression-free survival (PFS).


Data on Furmonertinib for EGFR 20 exon insertion mutations issued at ESMO 2021

The excellent efficacy and safety of Furmonertinib is expected to bring a new option to patients with EGFR 20 exon insertion mutations.


Furmonertinib has been included in 27 drug catalogues of inclusive medical insurance

Adhering to its philosophy of "Advancing Long Life with Innovation of Science and Technology", Allist is actively supporting and participating in this innovative and beneficial medical insurance model to accelerate the adding of Furmonertinib to the catalogues of local inclusive medical insurance.

Jihao Du Allist Chairman express:The Q3 financial resport of Allist has achieved the high-profile profit target,offering a gift for the up coming first anniversary of Allist's listing.The strong performance in Q3 will add momentum to Allist's all projects that are advancing at full speed.Give this positive growth trend,I believe that our year-end performance will surely hit a new high.